Wealth Advisory Investment Director Steve Christ GUARANTEES you'll:

Make 66% On This Biotech Stock

Or he'll personally pay you back 100%


Dear Reader,

I don't make claims like this often.

But when Steve Christ told me about his research on a revolutionary biotech company — one that's at the top of Big Pharma's buyout list — I sat right down to write this letter.

You see, not only is this company working on the cure to one of the deadliest diseases known to man, it's also following an enormously profitable trend in the biotech sector.

Here's what I mean...

Earlier this year, a four-year-old Massachusetts-based biotech company with just 60 employees was bought out by a pharmaceutical giant for $720 million.

Nearly a quarter billion for a company that didn't even have a product on the market.

It's just one of a number of such eye-popping buy-out deals that have been sweeping the biotech sector.

The reason behind it comes from CNN Money:

"Drug giants are desperate for growth and worried about the future, so they have been tripping over themselves to buy biotechs with decent profit potential — and bidding up the share prices of the whole group in the process." — July 29, 2009

For the 4-year-old start-up Sirtris Pharmaceuticals Inc., 'profit potential' was an anti-aging medicine.

Literally, a fountain of youth in pill form.

And this wonder drug — derived from red wine — had not even begun its clinical trials when the buyout was announced.

Because for Sirtris's buyer, GlaxoSmithKline (NYSE: GSK) — the sixth biggest Pharmaceutical company in the world — the motivation to buy wasn't mere short-term profit...

It was survival.

You see, Big Pharma's business model was on the brink of death.

On average, it takes 12 years and $800 million to patent a new drug... And it takes an additional ten years, after the patent has been awarded, to get FDA approval.

"Major drug makers have been hit with a series of key patent expirations, and subsequent generic competition is eating away at revenue. There is no system in place for approving generic versions of biotechnology-based drugs, leaving open the potential for more time on the market without competition, and thus more revenue." — PharmaManufacturing.com

By the time the new product brings in a single dollar of revenue, half of the patent's 20-year lifespan has already passed.

When the patent protection fades, the generics move in on the market by copying the now-unprotected formula and selling it at a discount.

In the next three years alone, generics are projected to absorb $67 billion of the pharmaceutical market.

In a market that's tougher than ever on needless spending, the name brands have seen the writing on the wall.

But here's how they're saving their own skins:

Instead of individually spending an average of $7.5 billion each year on costly research and development, only to lose their industrial secrets after a decade on the market...

The world's top 20 pharmaceutical companies are paying smaller companies to do their legwork for them.

quote 2

Which is how small, young startups like Sirtris can get snapped for $720 million in cash... even while their drugs are still just in the development phase.

And why investors like you were able to pull in 187% gains as the share price skyrocketed from $12 to $22 in just a few months.

Fortunately, lightening is about to strike again.

In the next few minutes, I'm going to tell you about Big Pharma's next big prospect... the company for which my colleague Steve Christ is guaranteeing 66% gains... at a minimum.

And I'd like you to see exactly what this aggressive buy-out campaign can do for your bottom line.

How Big Pharma 'Shake and Bakes' Research and Development

Right now, the market for biotech startups is at an all-time high.

Companies that you've never heard of that are on the verge of major breakthroughs... selling for BILLIONS.

Companies like Medarex Inc., which was recently bought out by Bristol-Myers Squibb.

chart_1

In the five months following the $2.4 billion buyout, the stock price grew over 450%.

Or Cougar Biotech, which was acquired by Johnson & Johnson in May 2009 for $1 billion in cash.

chart1a

Its share value more than doubled in less than three months.

And that was long before the results were known from Cougar's two key Phase III trials.

Big Pharma's
Latest Buyouts:

"The newest offers, including Roche's $89-per-share bid, helped push Genentech shares up 20 percent to more than $98, implying that investors expect a higher offer. The stock closed at $81.82 July 18, the session before Roche made the offer. ImClone Systems Inc.'s stock surged 38 percent to $63.93 July 31, after Bristol-Myers offered $60 per share. The value has hovered at around $64." — Associated Press

For a company the size of Johnson and Johnson, the risk was more than worth it.

Just like these were:

Big Pharma's Recent Hit List:

These companies made multi-millionaires of its financiers... just like Sirtris did when its anti-aging technology turned into a $720 million cash purchase.

Today, there's a company that's working on just such a miracle drug.

Its goal has been one of the most elusive in all of medical history.

In short, this company is working towards...

Killing the Killer:
Could Cancer's End Be In Reach?

According to the American Cancer Institutes, it cost the American economy $228.1 Billion in 2008...

...As it took 565,000 American lives.

Its death rate has gone virtually unchanged since 1950.

And over the next decade, 6 million more American families will feel the loss of a loved one to cancer.

graph

But for the first time ever, one of humanity's oldest and deadliest diseases may have finally met its match.

A Technology That Can 'Order' A Tumor...

To Shrivel Up And Die

The technology was made possible by the discovery of an enzyme called telomerase.

When this enzyme is overproduced, cells divide indefinitely without aging...

And it's this uncontrolled cell division that creates malignant tumors... cancer.

quote 1

This discovery is so important that it could change the face of medicine forever.

In fact, the three university researchers who discovered it were awarded 2009's Nobel Prize in medicine.

And it's all leading to...

The Biotech Play Guaranteed To Make 66%...

Or Your Money Back

Truth is for this biotech company, the cure for cancer may be just the beginning.

That's because the company that figures out how to manipulate telomerase with reliability... will have the world's population in its hands.

Not only will they be able to make cancer cells wither and die...

It will also slow down the aging process of healthy cells.

And that's exactly what this company is perfecting today.

It's pioneering the science of regenerative medicine... by literally creating new tissue. (This is the same company that developed a spinal drug that allowed paralyzed rats to walk once again.)

Right now, their new generation of anti-cancer drugs is in Phase 2 trials. And a major pharmaceutical company is highly interested in the technology.

The telltale signs are all there:

chart

The value of this stock has been rising — slowly but steadily — since early on in the buyout boom.

But just recently, the number of call options has shot up dramatically...

...With the January call volume growing to over 10 times that of November's.

If these options investors are right, the price of the stock will rise 66% in the next three months alone!

Making it one of the hottest — yet one of the most classified — stocks in the biotech market today.

So let me reiterate the guarantee I gave you just a few minutes ago...

If you don't make 66% on your investment by May 1, 2010, I'll give you a 100% refund.

That's my promise to you — no fine print, no loopholes.

Make 66% by May 1, or I'll issue a refund for the full amount. No processing fees or penalties...

No questions asked.

The last time we did this, we promised double-digit gains... but did much, much better than that.

In fact, we ended up closing a 70% gain in just 25 days!

This time, the absolute minimum I'll accept will be 66%!

The promise may be bold, but it's the result of the sort of painstaking research and analysis our readers depend on.

And it's all part of...

The Wealth Advisory's Biotech Breakout

I have to fill you in on my colleague, Steve Christ.

"In 2008, Pharma swallowed some $28.5 billion worth of U.S. biotech companies, just a few billion short of a $33 billion record in 2007. And if you back out AstraZeneca's 2007 buyout of vaccine maker MedImmune -- a whopping $15.6 billion deal - -then 2008 totted up the highest biotech M&A total ever." — Ernst and Young

Steve and I have been writing about the simmering biotech market for over a year now...

And our recommendations have earned investors millions.

We know all too well... to be on top of this business means always being the first to know.

It's on this principle that Steve has developed his Wealth Advisory service as a vehicle for investors like you to capitalize on special situations... just like the one we're staring down in biotech these days.

Because with each "big picture" opportunity comes a chance to employ a carefully-selected investment and get in ahead of the masses.

That's why it's so important for you have an appropriate, rock-solid investment philosophy... as well as sound research and advice.

The Wealth Advisory goes far beyond winning stock picks. Our focus is a philosophy that can help members build a lifetime of wealth in any market.

And right now, with the biotech market as explosive as ever, there may not be a more legitimate quick-gaining trade out there today.

With buyouts like those I mentioned earlier, and the recent acquisition of Opexa (NASDAQ: OPXA), a company valued at just $6 million, by Novataris (NYSE: NVS), for $50 million...

quote2

The trend is one of the most consistent — and potentially one of the most profitable — in decades.

And it's brought us the kind of opportunity that can bring the same double-digit gains Wealth Advisory members have come to expect from us.

Specifically, I'm referring to...

Net Cumulative Gains of 677.5%...
in the Midst of the Worst Bear Market in Decades

Let's face it...

When we launched the Wealth Advisory in March 2008, our timing couldn't have been worse.

After all... seven months later, the market totally collapsed.

"A buyout bull's-eye will likely remain on biotechnology companies over the next few years..."
— Associated Press

In fact, since we started the Wealth Advisory, the Dow has dropped 31.9%... the NASDAQ has dropped 25.2%... and the S&P500 is down 36.8%.

So how have Wealth Advisory subscribers done during this difficult time?

We've posted a net gain of 648% on our closed positions, delivering 30 winners versus only 10 losers.

Don't Just Take My Word for It...

"Your recommendation has actually saved my portfolio! Thanks!" — Roger from San Diego

"Here's how I'm doing with your recommendations. I purchased 5,000 shares at $5.80 per share. I'm doing quite well and kicking myself for not buying 10,000. Thanks!" — Don from Kansas City

"I am up 32% so far on this stock. Very pleasing given the market ups and downs! Keep 'em coming. Cheers." — Patrick from Connecticut

Here's a peek at just a few of those closed positions so you can see for yourself just what kind of gains are possible — no matter what kind of market we're in...

The gains don't end there...

Again... that's a cumulative gain of 776.7% versus losses of only 99.2 % or a net gain of 677.5%!

Here's what we did with Orexigen Therapeutics and its weight loss drug, Contrave:

orexigen


This is just the beginning for biotechs in the short term.

And I want you to join us in pursuit of their biggest gains.

Here's How You Can Get Started Today

Step One — Sign up for a risk-free trial subscription to The Wealth Advisory. The minute you sign up, you'll be granted immediate access to our new report:

In it, you'll find three winning biotech plays, including the company about to deliver the "twitch heard around the world."

Addtionally -- at no extra cost -- you'll also receive our most recent reports on commercial real estate, and how to profit from its collapse.

They include:

Step Two — Read the reports as soon as you can... and simply follow the step-by-step instructions I've provided. You'll be armed with all the information you need to get started.

And as far as timing and strategy go, we've got you covered there, too...

After signing up, you'll immediately start receiving:

And after you get our up-to-the-minute research reports, I encourage you to take a look around our members-only website. While you're there you'll have full access to the Wealth Advisory archives as well as our complete portfolio.

Now here's what we're asking...

The one-year subscription price for the Wealth Advisory is $79.

For roughly $1.50 per week, you'll get our FREE research reports... and access to a portfolio that has produced a cumulative net gain of 677% in the past 18 months alone.

But that's not all. hmm book

Right now, thanks to a special arrangement I have with Wealth Advisory friend and best-selling author Peter Schiff, I'm authorized to give you a free copy of his brand-new book, Crashproof 2.0: How To Profit From The Economic Collapse, when you sign up for a 2-year subscription. It's the sequel to his bestseller, Crashproof, where Schiff predicted the meltdown of 2008.

And remember — you're protected at all times by our...

100% Iron-Clad Guarantee

We're so confident that you'll be more than satisfied with the research and recommendations found in the Wealth Advisory that we're willing to assume all of the risk for your subscription.

If by May 1, this biotech recommendation fails to gain at least 66% from its price on the date of issue...

Just call us and I'll return every penny you paid — no questions asked.

Plus, you can keep the four special reports as my gift to you.

All you have to do is click on the button below to get started.

To Your Wealth,

Brian Hicks
Publisher, The Wealth Advisory

P.S. There is no commodity more valuable than information. And what I uncovered just yesterday — during a lunch with a biotech CEO whose company is pioneering immuno-stimulating medicine — may change the way we all think about vaccines. Become a Wealth Advisory member today, and be among the first to receive my forthcoming report on the next 'paradigm shift' in the drug industry. Just click here.